Skip to main content

View full-text article in PMC

. 2020 Aug 3;117(33):20004–20014. doi: 10.1073/pnas.2005052117

Table 1.

Median inhibitory concentrations for BTZ and CFZ in KRAS and NRAS WT and mutant ANBL-6 and U266 myeloma cells

	KRAS variants			NRAS variants
	WT (nM)	G12V (nM)	S17N (nM)	WT (nM)	G12V (nM)	S17N (nM)
ANBL-6
BTZ	7 ± 0.25	16 ± 0.85	2.5 ± 0.19	11.5 ± 0.05	18 ± 0.25	3.5 ± 0.057
BTZ	7 ± 0.25	P = 0.031^*	2.5 ± 0.19	11.5 ± 0.05	P = 0.052^*	3.5 ± 0.057
CFZ	4.5 ± 0.28	12 ± 0.57	1.3 ± 0.21	6 ± 0.82	11.8 ± 1.06	3.6 ± 0.20
CFZ	4.5 ± 0.28	P = 0.031^*	1.3 ± 0.21	6 ± 0.82	P = 0.031^*	3.6 ± 0.20
U266
BTZ	0.9 ± 0.03	6.5 ± 0.33	0.1 ± 0.01	0.56 ± 0.02	1.8 ± 0.21	0.11
BTZ	0.9 ± 0.03	P = 0.041^*	0.1 ± 0.01	0.56 ± 0.02	P = 0.031^*	0.11
CFZ	0.82 ± 0.03	3.5 ± 0.12	0.32 ± 0.02	0.42 ± 0.027	1.2 ± 0.034	0.2 ± 0.018
CFZ	0.82 ± 0.03	P = 0.031^*	0.32 ± 0.02	0.42 ± 0.027	P = 0.031^*	0.2 ± 0.018

^*

P values are for the comparison between the G12V variants and the WT NRAS or KRAS.